When Time Gets Compressed, Operations Gets Squeezed

Upstream delays — protocol development, regulatory input, scientific revisions — are often accepted as part of the process.

But once timelines reach operations, the conversation shifts:

  • Can we find efficiencies in conduct?

  • Can we compress vendor selection?

  • Can we recover time?

  • Can we still hit FPI?

I’ve been asked — sometimes all the way up to the CEO — to deliver FPI on time with less time to work with.

That pressure is real. And it changes behavior.

The FPI Trap (as an example)

When FPI becomes the dominant objective, priorities shift:

  • Internal teams front-load effortFastest-starting countries move to the top

  • A handful of high-performing sites get accelerated

  • Contracts are rushed for early enrollment sites

You use relationships. You use leverage. You push hard.

And sometimes you hit FPI.

But FPI is First Patient In. It is not Last Patient Out.

The real objective is sustainable enrollment and clean, analyzable data at database lock.

Where Early Momentum Can Create Hidden Risk

A strong start is not the problem. The risk appears when early acceleration distorts long-term structure.

Examples I’ve seen:

  • Front-loaded cost pressure that leads to mid-study change orders

  • Under-resourced teams that burn out during enrollment ramp-up

  • Aggressive early commitments that create unrealistic expectations

  • Country and site mix decisions optimized for optics rather than durability

There’s also a quieter risk.

When you invest significant effort — political capital, personal credibility, team energy — to hit FPI and still miss it, the internal impact is real:

  • The team is exhausted

  • Confidence drops

  • Momentum becomes harder to rebuild

  • Leadership pressure increases

Now you’re starting the long haul from a weaker position.

Article content

Designing for Sustainability, Not Optics

Trials often run 12, 24, 36, even 48 months.

So milestones or study planning should be evaluated against three questions:

  • Is this milestone politically important — or structurally important?

  • Does this acceleration borrow capacity from future phases?

  • If enrollment doubles in six months, will this structure hold?

If the answers are unclear, the risk isn’t visible yet — but it’s accumulating.

I my opinion, strong operations leadership is about protecting the study from instability long after the milestone disappears from the executive dashboard.

That discipline — designing for sustainability — is what ultimately determines outcomes.

What We Do at Clin.AI

At Clin.AI, we help sponsors bring greater structure and transparency to vendor selection and vendor management — making it easier to set studies up correctly from the start and keep them on track, within budget, and delivered on time.

If you’d like to strengthen your vendor selection/oversight and gain real-time visibility into the progress of your trials, give us a call. We’d be happy to walk you through how we can support your goals.

If that resonates with you, we’d love to show you how Clin.AI works.

About the Author

Kalyan Obalampalli (KO) is the Founder and President of Clin.AI, a disruptive start-up transforming how biotech and pharma sponsors select and manage vendors. With more than 20 years of leadership experience in clinical operations and outsourcing at major pharma and biotech companies, KO brings a unique perspective on how technology can close long-standing gaps in clinical development.

#ClinicalOperations #VendorSelection #VendorManagement #ClinicalTrials #Biotech #KOscorner